Skip to content

Study · Animal study (in vivo) · mouse · 2021

3 results

Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins.

Whitson JA, Martín-Pérez M, Zhang T, Gaffrey MJ, Merrihew GE, Huang E, White CC, Kavanagh TJ, Qian WJ, Campbell MD, Campbell MD, MacCoss MJ, Marcinek DJ, Villén J, Rabinovitch PS

GeroScience4 Sept 2021Cited by 28 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In old mice, 8 weeks of elamipretide almost completely reversed the age-related increase in heart protein S-glutathionylation.

    In plain wordsIn old mice, elamipretide almost fully reversed an age-related rise in protein oxidation in the heart.

    Outcome
    DecreaseAge-related protein S-glutathionylation in heart
    Study

    mousen: not reported in source

    Old (24 months at start) mouse heart
    Outcome group
    Aging markers · Cardiovascular
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    This shift in the oxidation state of the proteome was almost completely reversed by 8 weeks of treatment with elamipretide.
    1 context sentence
    Summary · context
    Aging led to an increase in oxidation of protein thiols demonstrated by increased S-glutathionylation of cysteine residues on proteins from Old (24 months old at the start of the study) mouse hearts compared to Young (5-6 months old).
  2. 02AnimalAnimal study (in vivo)Mechanism

    In old mice, elamipretide partially restored some age-associated changes in the heart phosphoproteome.

    In plain wordsIn old mice, elamipretide partly restored some age-related changes in heart protein phosphorylation.

    Outcome
    MixedAge-related changes in heart phosphoproteome
    Study

    mousen: not reported in source

    Old (24 months at start) mouse heart
    Outcome group
    Aging markers · Cardiovascular
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    We also found changes in the mouse heart phosphoproteome that were associated with age, some of which were partially restored with elamipretide treatment.
    1 context sentence
    Summary · context
    Aging led to an increase in oxidation of protein thiols demonstrated by increased S-glutathionylation of cysteine residues on proteins from Old (24 months old at the start of the study) mouse hearts compared to Young (5-6 months old).
  3. 03AnimalAnimal study (in vivo)Mechanism

    In old mice, elamipretide treatment did not affect the age-related changes in Myot S231 and cMyBP-C S307 peptides.

    In plain wordsIn old mice, elamipretide did not change the age-related shifts seen at two specific heart protein sites.

    Outcome
    No significant changeMyot S231 and cMyBP-C S307 age-related changes
    Study

    mousen: not reported in source

    Old (24 months at start) mouse heart
    Outcome group
    Aging markers · Cardiovascular
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Parallel reaction monitoring of a subset of phosphorylation sites revealed that the unmodified peptide reporting for Myot S231 increased with age, but not its phosphorylated form and that both phosphorylated and unphosphorylated forms of the peptide covering cMyBP-C S307 increased, but that elamipre…
    1 context sentence
    Summary · context
    Aging led to an increase in oxidation of protein thiols demonstrated by increased S-glutathionylation of cysteine residues on proteins from Old (24 months old at the start of the study) mouse hearts compared to Young (5-6 months old).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.